The Russian government plans to provide support to producers of cheap drugs, with the aim to prevent their disappearance from the domestic market, according to recent statements by representatives of some senior state officials and industry’s analysts, reports The Pharma Letter’s local correspondent.
As drugmakers have recently informed, the production of about 50 drugs (many of which are in the list of vital medicines) and their imports to the Russian market will be suspended within the next several months, due to low profits, associated with such production and supplies.
Such plans of producers may create a shortage of certain drugs in the Russian market and has already sparked concerns from the government.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze